HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

House Appropriators Stoke Flames For FDA Regulation On CBD In Supplements

Executive Summary

House Appropriations subcommittee with FDA oversight makes clear in questions for Commissioner Gottlieb they support allowing use of constituent ingredients from hemp and cannabis plants in food and dietary supplement products. Members also press for approving US firms' applications for pharmaceuticals with cannabis-derived active ingredients. Gottlieb announces working group will guide FDA decisions on potential CBD-use rulemaking.

You may also be interested in...



Legislating US Regulatory Pathway For Cannabinoids ‘Not End of The World’ – Gottlieb

Former FDA commissioner says legislative carve-out for a regulatory pathway for cannabinoids is a better option than a rulemaking, which could take five years and “may not even work.” Cannabinoids market is “well far ahead of where the regulation is,” he says.

If Safety Data Open Door In US, Cannabinoids’ Lawful Use In Supplements At Least A Year Off

At FDLI annual meeting, attorneys cast doubt on CBD rules outlook. Paul Joseph says regulations are at least a year away while Jonathan Havens doubts FDA is even working on regulations, including GMPs, because it is still asking industry for specific safety details.

Safe Level For CBD As Dietary Ingredient? FDA Continues Data Review

Associate commissioner Lowell Schiller's comments at recent trade group regulatory conference mark agency's first public statement on likely direction on CBD's use in food, supplements. Potentially allowing CBD's use also is making FDA "think about whether we have the tools and resources we need to take this on," Schiller said.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS148589

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel